At this point, compounds were added at 5 M, either alone or in combination with emricasan (25 M) or liproxstatin 1 (1 M)
Code year: FY2026 (Oct 1 2025 Sep 30 2026) Audience: Certified Coders, Auditors and Clinical Documentation Specialists Access: CCO Members Last updated: April 2026 This Clinical Documentation Guide (CDG) provides AAPC/AHIMA-credentialed coders and CDI specialists with comprehensive guidance for coding obesity, overweight, and body mass index (BMI) conditions under FY2026 ICD-10-CM (effective October 1, 2025 September 30, 2026)
Additionally, those with a history of pancreatitis, severe gastrointestinal disorders, or allergies to any components of the medication may not be good candidates
This is because flavonoids with catechol groups, such as EC and CH, lacks conjugation to the 3-OH group in C-ring which shield such molecules to form ( p )para-quinone methides, and thus, flavonoids with these structural properties restrict their oxidation at the B-ring by the tyrosinase enzyme 104
Latest Phase 3 Trial Results: TRIUMPH-1 (May 2026) On 21 May 2026, Eli Lilly announced topline results from TRIUMPH-1 , the largest and longest Phase 3 obesity trial conducted for Retatrutide to date
